8-K filed Jun 22, 2026 at 16:10 ET
Arvinas (ARVN) filed an 8-K announcing the departure of Chief Medical Officer Dr. Noah Berkowitz, effective July 3, 2026, with a search for a replacement underway. The departure is described as voluntary to pursue other opportunities, with standard severance including 9 months base salary and accelerated vesting of RSUs through May 9, 2027. This is a routine officer departure for a biotech company, the CMO role is important but not a CEO/CFO-level exit, and the filing lacks any financial data or guidance changes.